Standard and controversies in sentinel node in breast cancer patients

被引：0
作者：
Veronesi, P. [1 ,2 ]
Corso, G. [1 ,2 ]
机构：
[1] IRCCS, European Inst Oncol, Breast Surg Div, Milan, Italy
[2] Univ Milan, Fac Med, Milan, Italy
来源：
BREAST | 2019年 / 48卷
关键词：
Breast cancer; Sentinel lymph node biopsy; Axillary dissection; Breast conserving surgery; Mastectomy; AXILLARY DISSECTION; FOLLOW-UP; BIOPSY; CHEMOTHERAPY; MULTICENTER; TRIAL;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Axillary management in breast cancer is still controversial. Recent clinical trials have clearly demonstrated that in breast-conserving surgery, axillary dissection could be an overtreatment when metastases are present in only 1-2 sentinel lymph nodes. Nonetheless, axillary dissection remains the principal treatment in patients undergoing mastectomy with at least one metastatic sentinel lymph node and in patients eligible for breast conserving surgery with three or more positive sentinel lymph nodes. In this analytical review, we discuss the clinical evidence, taking into account recent guidelines, for axillary management. (C) 2019 Elsevier Ltd. All rights reserved.
引用
收藏
页码：S53 / S56
页数：4
相关论文
共 20 条
  • [1] Improved False-Negative Rates with Intraoperative Identification of Clipped Nodes in Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy
    Cabioglu, Neslihan
    Karanhk, Hasan
    Kangal, Dilek
    Ozkurt, Enver
    Oner, Gizem
    Sezen, Fatma
    Yilmaz, Ravza
    Tukenmez, Mustafa
    Onder, Semen
    Igci, Abdullah
    Ozmen, Vahit
    Dinccag, Ahmet
    Engin, Gulgun
    Muslumanoglu, Mahmut
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (10) : 3030 - 3036
  • [2] Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study
    Classe, Jean-Marc
    Loaec, Cecile
    Gimbergues, P.
    Alran, S.
    de Lara, C. Tunon
    Dupre, P. F.
    Rouzier, Roman
    Faure, C.
    Paillocher, N.
    Chauvet, M. P.
    Houvenaeghel, G.
    Gutowski, M.
    De Blay, P.
    Verhaeghe, J. L.
    Barranger, E.
    Lefebvre, C.
    Ngo, C.
    Ferron, G.
    Palpacuer, C.
    Campion, L.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (02) : 343 - 352
  • [3] Corso G, 2017, ANN ITAL CHIR, V88, P202
  • [4] De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
    Curigliano, G.
    Burstein, H. J.
    Winer, E. P.
    Gnant, M.
    Dubsky, P.
    Loibl, S.
    Colleoni, M.
    Regan, M. M.
    Piccart-Gebhart, M.
    Senn, H. -J.
    Thurlimann, B.
    Andre, F.
    Baselga, J.
    Bergh, J.
    Bonnefoi, H.
    Brucker, S. Y.
    Cardoso, F.
    Carey, L.
    Ciruelos, E.
    Cuzick, J.
    Denkert, C.
    Di Leo, A.
    Ejlertsen, B.
    Francis, P.
    Galimberti, V.
    Garber, J.
    Gulluoglu, B.
    Goodwin, P.
    Harbeck, N.
    Hayes, D. F.
    Huang, C. -S.
    Huober, J.
    Khaled, H.
    Jassem, J.
    Jiang, Z.
    Karlsson, P.
    Morrow, M.
    Orecchia, R.
    Osborne, K. C.
    Pagani, O.
    Partridge, A. H.
    Pritchard, K.
    Ro, J.
    Rutgers, E. J. T.
    Sedlmayer, F.
    Semiglazov, V.
    Shao, Z.
    Smith, I.
    Toi, M.
    Tutt, A.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (08) : 1700 - 1712
  • [5] De Cicco C, 1998, J NUCL MED, V39, P2080
  • [6] Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
    Donker, Mila
    van Tienhoven, Geertjan
    Straver, Marieke E.
    Meijnen, Philip
    van de Velde, Cornelis J. H.
    Mansel, Robert E.
    Cataliotti, Luigi
    Westenberg, A. Helen
    Klinkenbijl, Jean H. G.
    Orzalesi, Lorenzo
    Bouma, Willem H.
    van der Mijle, Huub C. J.
    Nieuwenhuijzen, Grard A. P.
    Veltkamp, Sanne C.
    Slaets, Leen
    Duez, Nicole J.
    de Graaf, Peter W.
    van Dalen, Thijs
    Marinelli, Andreas
    Rijna, Herman
    Snoj, Marko
    Bundred, Nigel J.
    Merkus, Jos W. S.
    Belkacemi, Yazid
    Petignat, Patrick
    Schinagl, Dominic A. X.
    Coens, Corneel
    Messina, Carlo G. M.
    Bogaerts, Jan
    Rutgers, Emiel J. T.
    [J]. LANCET ONCOLOGY, 2014, 15 (12) : 1303 - 1310
  • [7] FISHER B, 1977, CANCER-AM CANCER SOC, V39, P2827, DOI 10.1002/1097-0142(197706)39:6<2827::AID-CNCR2820390671>3.0.CO
  • [8] 2-I
  • [9] Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment
    Galimberti, V.
    Fontana, S. K. Ribeiro
    Maisonneuve, P.
    Steccanella, F.
    Vento, A. R.
    Intra, M.
    Naninato, P.
    Caldarella, P.
    Iorfida, M.
    Colleoni, M.
    Viale, G.
    Grana, C. M.
    Rotmensz, N.
    Luini, A.
    [J]. EJSO, 2016, 42 (03): : 361 - 368
  • [10] Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled, phase 3 trial
    Galimberti, Viviana
    Cole, Bernard F.
    Viale, Giuseppe
    Veronesi, Paolo
    Vicini, Elisa
    Intra, Mattia
    Mazzarol, Giovanni
    Massarut, Samuele
    Zgajnar, Janez
    Taffurelli, Mario
    Littlejohn, David
    Knauer, Michael
    Tondini, Carlo
    Di Leo, Angelo
    Colleoni, Marco
    Regan, Meredith M.
    Coates, Alan S.
    Gelber, Richard D.
    Goldhirsch, Aron
    [J]. LANCET ONCOLOGY, 2018, 19 (10) : 1385 - 1393
12